1.
Change of initial oral antidiabetic therapy in type 2 diabetic patients
2.
IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings
The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density
Vascular outcomes in patients with screen-detected or clinically diagnosed type 2 diabetes: Diabscreen study follow-up
Yield of opportunistic targeted screening for type 2 diabetes in primary care: The Diabscreen study
Classification of Recombinant Biologics in the EU: Divergence between National Pharmacovigilance Centers
3.
4.
5.
Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: Association with IA-2 and islet cell autoantibodies